ProKidney (PROK): Chief Regulatory Officer Weber Darin J. converted options into 200,000 shares (SEC Form 4)
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for PROK
Across the 11 sessions after earlier PROK headlines, the stock closed higher 6 times and lower 5 times, with a median move of 3.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PROK | SPY |
|---|---|---|---|
| Oct 22, 2026 | ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Updateand 1 other headline that session | -0.7% | -1.2% |
| Oct 2, 2026 | ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 | +0.6% | +0.7% |
| Aug 11, 2026 | ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights | -4.7% | -0.3% |
| Jun 2, 2026 | ProKidney Appoints Kenneth Locke as Chief Technical Officer | +2.7% | +0.1% |
| May 15, 2026 | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | -2.9% | -1.2% |
| Mar 26, 2026 | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | -3.3% | -1.8% |
Earlier insider filings at PROK
- Aug 20, 2026Director Pereira Brian Jg sold $1,067,773 worth of shares (757,164 units at $1.41), closing all direct ownership in the company (SEC Form 4)
- Aug 6, 2026Director Pereira Brian Jg converted options into 757,164 shares (SEC Form 4)
- Jul 6, 2026SEC Form 4 filed by Chief Technical Officer Locke Kenneth Thomas
- Jun 15, 2026Chief Legal Officer Girolamo Todd C converted options into 163,857 shares, increasing direct ownership by 100% to 327,713 units (SEC Form 4)
- May 29, 2026SEC Form 4 filed by Director Jimenez Santos Jose Ignacio
Keep researching PROK
- PROK insider tradesEvery buy and sale reported by ProKidney Corp. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- PROK financial statementsRevenue, profit, cash flow and balance sheet from ProKidney Corp.'s SEC filings.
Quantisnow market dataNASDAQ
PROK
ProKidney Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for PROK
Full PROK profile on Quantisnow Follow PROK and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time